HIV1 protease inhibitor lipodystrophy
Jump to navigation
Jump to search
Introduction
A lipodystrophy syndrome resulting from therapeutic use of antiretroviral protease inhibitors in the treatment of patients with AIDS.
Etiology
Pathology
- thought to be secondary to inhibition the low-density lipoprotein (LDL) receptor related protein (LRP)
Clinical manifestations
- central visceral redistribution of fat
- wasting of extremities
- hyperlipidemia
- insulin resistance
Management
- statins of limited (if any) benefit[1]
- metformin & statin therapy for patients with insulin resistance & hyperlipidemia[2]
- tesamorelin can reduce fat accumulation but does not treat insulin resistance or hyperlipidemia[2]
More general terms
Additional terms
- CD91, low density lipoprotein (LDL) receptor related protein (LRP) 1, apolipoprotein E [apoE] receptor 1, chylomicron remnant receptor or alpha-2 macroglobulin receptor
- HIV1 infection; human immunodeficiency virus-1 infection
- protease inhibitor
References
- ↑ 1.0 1.1 Mallon PWG et al, Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - A randomized. placebo-controlled study, AIDS 2006; 20:1003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16603852
Gharakhanian S et al, Statins in HIV-associated lipodystrophy and metabolic syndrome: Is there a missing link? AIDS 2006; 20:164 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16603860 - ↑ 2.0 2.1 2.2 NEJM Knowledge+ Endocrinology